Lixisenatide antidiabetic drugs

AQVE-10010 - Lixisenatide - AVE-0010 - AVE0010 - AVE 0010 - ZP10A peptide



Trial Studied treatment Control Patients Size Study type Results NCT

Diabetes type 2 - insulin secretagogues peptides (incretins) in all type of patients - antidiabetic drugs in Patients inadequately controlled on MET+SU therapy - antidiabetic drugs in patients with insufficient glycaemic control with bitherapy - antidiabetic drugs in patients inadequately controlled with insulin - antidiabetic drugs in patients inadequately controlled on metformin - antidiabetic drugs in patients inadequately controlled on monotherapy - insulin therapy in all type of patients - glucose lowering for cardiovascular prevention in all type of patients

GETGOAL-MONO Japan LTS ongoing lixisenatidecontrolNA NCT00905255
GetGoal-X ongoing lixisenatideexenatideNA Exploratory NCT00707031
GETGOAL-Llixisenatideglargine once daily495 (328/167) NCT00715624
ELIXAlixisenatideplacebo6068 Exploratory NCT01147250
ELIXA (EFC11319) ongoing lixisenatideplaceboNA NCT01147250
GETGOAL-MONO ongoing lixisenatideplaceboNA NCT00688701
GetGoal Duo1 ongoing lixisenatideplacebo (add on basal insulin)NA NCT00975286
GETGOAL-Llixisenatideplacebo (add on basal insulin)495 (328/167) NCT00715624
GETGOAL-L-ASIA ongoing lixisenatideplacebo (add on basal insulin)NA NCT00866658
GETGOAL-F1 ongoing lixisenatideplacebo (add on MET)NA NCT00763451
GETGOAL-M ongoing lixisenatideplacebo (add on MET)NA NCT00712673
Ratner DRI6012, 2010lixisenatideplacebo (add on MET)542 (433/109) Exploratory NCT00299871
GetGoal-M-As ongoing lixisenatideplacebo (add on MET+/-SU)NA NCT01169779
GETGOAL-S ongoing lixisenatideplacebo (add on SU+/-MET)NA NCT00713830
GETGOAL-P ongoing lixisenatideplacebo (add on TZD+/-MET)NA NCT00763815
EFC10780, 2010 ongoing lixisenatidesitagliptin (add on MET)NA NCT00976937